

Lei Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2733542/publications.pdf>

Version: 2024-02-01

35
papers

2,533
citations

236925

25
h-index

377865

34
g-index

37
all docs

37
docs citations

37
times ranked

3616
citing authors

#	ARTICLE	IF	CITATIONS
1	CGCG clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2016, 375, 263-273.	7.2	448
2	Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner. <i>Oncotarget</i> , 2015, 6, 537-546.	1.8	207
3	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021, 499, 60-72.	7.2	194
4	A novel cell cycle-associated lncRNA, HOXA11-AS, is transcribed from the 5-prime end of the HOXA transcript and is a biomarker of progression in glioma. <i>Cancer Letters</i> , 2016, 373, 251-259.	7.2	156
5	DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. <i>Cancer Letters</i> , 2015, 359, 198-205.	7.2	148
6	LncRNA profile of glioblastoma reveals the potential role of lncRNAs in contributing to glioblastoma pathogenesis. <i>International Journal of Oncology</i> , 2012, 40, 2004-12.	3.3	135
7	HOTAIR is a therapeutic target in glioblastoma. <i>Oncotarget</i> , 2015, 6, 8353-8365.	1.8	105
8	MicroRNA-21 Expression is regulated by β -catenin/STAT3 Pathway and Promotes Glioma Cell Invasion by Direct Targeting RECK. <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 573-583.	3.9	91
9	Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy. <i>Advanced Materials</i> , 2019, 31, e1805697.	21.0	84
10	EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma. <i>Cancer Letters</i> , 2015, 356, 929-936.	7.2	81
11	JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1229-1243.	1.2	74
12	A lentivirus-mediated miR-23b sponge diminishes the malignant phenotype of glioma cells in vitro and in vivo. <i>Oncology Reports</i> , 2014, 31, 1573-1580.	2.6	72
13	STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo. <i>Oncology Reports</i> , 2014, 31, 2173-2180.	2.6	68
14	Targeted design and identification of AC1NOD4Q to block activity of HOTAIR by abrogating the scaffold interaction with EZH2. <i>Clinical Epigenetics</i> , 2019, 11, 29.	4.1	63
15	Inactivation of PI3K/AKT signaling inhibits glioma cell growth through modulation of β -catenin-mediated transcription. <i>Brain Research</i> , 2010, 1366, 9-17.	2.2	50
16	AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis. <i>Cancer Letters</i> , 2015, 362, 174-182.	7.2	50
17	EGFRvIII/integrin β 3 interaction in hypoxic and vitronectin-enriching microenvironment promote GBM progression and metastasis. <i>Oncotarget</i> , 2016, 7, 4680-4694.	1.8	50
18	PEG/RGD-modified magnetic polymeric liposomes for controlled drug release and tumor cell targeting. <i>International Journal of Pharmaceutics</i> , 2012, 426, 170-181.	5.2	48

#	ARTICLE	IF	CITATIONS
19	PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma. <i>Cancer Letters</i> , 2019, 443, 91-107.	7.2	43
20	Reprogramming carcinoma associated fibroblasts by AC1MMYR2 impedes tumor metastasis and improves chemotherapy efficacy. <i>Cancer Letters</i> , 2016, 374, 96-106.	7.2	39
21	Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas. <i>Frontiers in Immunology</i> , 2022, 13, 849592.	4.8	38
22	ICAT inhibits glioblastoma cell proliferation by suppressing Wnt/ β 2-catenin activity. <i>Cancer Letters</i> , 2015, 357, 404-411.	7.2	35
23	Polo-Like Kinase 4's Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 587554.	2.8	34
24	Combination treatment with doxorubicin and microRNA-21 inhibitor synergistically augments anticancer activity through upregulation of tumor suppressing genes. <i>International Journal of Oncology</i> , 2015, 46, 1589-1600.	3.3	33
25	MicroRNA-566 modulates vascular endothelial growth factor by targeting Von Hippel-Landau in human glioblastoma in vitro and in vivo. <i>Molecular Medicine Reports</i> , 2016, 13, 379-385.	2.4	28
26	Identification of miRNA-Mediated Core Gene Module for Glioma Patient Prediction by Integrating High-Throughput miRNA, mRNA Expression and Pathway Structure. <i>PLoS ONE</i> , 2014, 9, e96908.	2.5	26
27	γ 1 is Dysregulated at an Early Stage of Gliomagenesis and Suppresses Invasion Through Cytoskeleton Reorganization. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 429-437.	3.9	24
28	HOTAIR upregulates an 18-gene cell cycle-related mRNA network in glioma. <i>International Journal of Oncology</i> , 2017, 50, 1271-1278.	3.3	24
29	Construction of novel brain-targeting gene delivery system by natural magnetic nanoparticles. <i>Journal of Applied Polymer Science</i> , 2011, 121, 3446-3454.	2.6	22
30	Recent advances in unraveling the molecular mechanisms and functions of HOXA11's in human cancers and other diseases (Review). <i>Oncology Reports</i> , 2020, 43, 1737-1754.	2.6	19
31	Identification of a Core miRNA-Pathway Regulatory Network in Glioma by Therapeutically Targeting miR-181d, miR-21, miR-23b, β 2-Catenin, CBP, and STAT3. <i>PLoS ONE</i> , 2014, 9, e101903.	2.5	18
32	Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers. <i>Cancer Cell International</i> , 2021, 21, 566.	4.1	16
33	The role of N6-methyladenosine-modified non-coding RNAs in the pathological process of human cancer. <i>Cell Death Discovery</i> , 2022, 8, .	4.7	9
34	AKT1 and AKT2 promote malignant transformation in human brain glioma LN229 cells. <i>Clinical Oncology and Cancer Research</i> , 2011, 8, 144-148.	0.1	1
35	Brain Tumor Therapy: Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy (Adv. Mater. 19/2019). <i>Advanced Materials</i> , 2019, 31, 1970138.	21.0	0